



CSD/SE/UFR/2024-25
January 24, 2025

To
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai - 400001

To
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Subject: Integrated Filing (Financials) for the quarter ended December 31, 2024

.....

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financials) for the quarter ended December 31, 2024.

This is for your information and records.

Thanking you.
Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Company Secretary & Compliance Officer
FCS 12400

Encl.: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com




SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UN AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31, 2024.

Rs. In Lakhs							
STANDALONE							
Sl. No.	PARTICULARS	For the Quarter Ended			For the Nine Months period ended		For the year ended
		31/12/2024	30/09/2024	31/12/2023	31/12/2024	31/12/2023	31/03/2024
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	160.99	257.29	245.08	518.88	930.77	1,169.29
	Other Income	156.93	403.48	606.56	953.51	1,684.69	2,113.00
	Total income	317.92	660.77	851.64	1,472.39	2,615.46	3,282.29
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	486.58	520.34	432.04	1,475.88	1,307.02	1,653.37
	d) Finance costs	0.79	1.56	3.54	4.66	12.85	15.84
	e) Depreciation and amortisation expense	153.35	145.51	160.09	447.50	499.18	650.22
	f) R & D Expenses	826.49	908.96	618.85	2,194.43	1,621.28	2,038.87
	g) Other Expenses	177.90	191.59	114.00	550.89	409.23	570.72
	Total expenses	1,645.11	1,767.96	1,328.52	4,673.36	3,849.56	4,929.02
3	Profit before exceptional items & Tax (1-2)	(1,327.19)	(1,107.19)	(476.88)	(3,200.97)	(1,234.10)	(1,646.73)
4	Exceptional Items	-	-	-	-	745.66	745.66
5	Profit before Tax (3-4)	(1,327.19)	(1,107.19)	(476.88)	(3,200.97)	(488.44)	(901.07)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-	(100.24)
7	Net Profit/ (Loss) for the period/year(5-6)	(1,327.19)	(1,107.19)	(476.88)	(3,200.97)	(488.44)	(800.83)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(0.45)	(0.45)	4.75	(1.35)	14.24	(6.00)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(0.45)	(0.45)	4.75	(1.35)	14.24	(6.00)
9	Total Comprehensive Income for the period (7+8)	(1,327.64)	(1,107.64)	(472.13)	(3,202.32)	(474.20)	(806.83)
10	Paid-up equity share capital	2,180.74	2,180.74	2,180.74	2,180.74	2,180.74	2,180.74
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity						82,356.88
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(0.61)	(0.51)	(0.22)	(1.47)	(0.22)	(0.37)
	b) Diluted	(0.61)	(0.51)	(0.22)	(1.47)	(0.22)	(0.37)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the Nine Months period ended		For the year ended
		31/12/2024	30/09/2024	31/12/2023	31/12/2024	31/12/2023	31/03/2024
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	160.99	257.29	245.08	518.88	930.77	1,169.29
	Other Income	163.05	403.56	606.56	967.44	1,684.69	2,113.00
	Total Income	324.04	660.85	851.64	1,486.32	2,615.46	3,282.29
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	486.58	520.34	579.37	1,475.88	1,552.27	1,898.75
	d) Finance costs	0.79	1.56	3.54	4.66	12.85	15.84
	e) Depreciation and amortisation expense	153.35	145.51	160.29	447.50	499.38	650.22
	f) R & D Expenses	3,413.32	4,758.49	4,162.19	10,663.68	8,690.55	11,442.72
	g) Other Expenses	181.66	199.33	122.74	574.61	459.63	628.29
	Total expenses	4,235.70	5,625.23	5,028.13	13,166.33	11,214.68	14,635.82
3	Profit before exceptional items , Tax (1-2)	(3,911.66)	(4,964.38)	(4,176.49)	(11,680.01)	(8,599.22)	(11,353.53)
4	Exceptional Items	-	-	-	-	745.66	745.66
5	Profit before Tax (3-4)	(3,911.66)	(4,964.38)	(4,176.49)	(11,680.01)	(7,853.56)	(10,607.87)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-	(100.24)
7	Net Profit/ (Loss) for the period/year(5-6)	(3,911.66)	(4,964.38)	(4,176.49)	(11,680.01)	(7,853.56)	(10,507.63)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(0.45)	(0.45)	4.75	(1.35)	14.24	(6.00)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(0.45)	(0.45)	4.75	(1.35)	14.24	(6.00)
9	Total Comprehensive Income for the period (7+ 8)	(3,912.11)	(4,964.83)	(4,171.74)	(11,681.36)	(7,839.32)	(10,513.63)
10	Paid-up equity share capital Face Value of the Share	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00
11	Other Equity	-	-	-	-	-	24,823.32
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(1.79)	(2.27)	(1.92)	(5.36)	(3.60)	(4.82)
	b) Diluted	(1.79)	(2.27)	(1.92)	(5.36)	(3.60)	(4.82)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



NOTES:-

1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 24, 2025 . The results for the quarter ended December 31, 2024 has been reviewed by our statutory auditors

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences , Inc

4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5) The Company has allotted 7,26,91,239 equity shares amounting to Rs.39,980.18 lakhs through rights issue on November 16,2022.

Summary of Utilisation of Proceeds of Rights issue

Particulars	Amount Rs.In lakhs
Amout Raised through Rights Issue of Shares	39,980.18
Less: Rights Issue Expenses	(280.00)
Less: Amount Utilised	(37,490.74)
Balance Amount	2,209.44

6) The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, which provides for the issuance of 10,00,000 options, each option convertible into one equity share. Out of these, 6,20,000 options were granted by the Nomination & Remuneration Committee on May 6, 2024. For the period ended December 31, 2024, the employee benefit expense includes a charge of ₹75.37 Lakhs in respect of equity-settled share-based payment transactions, in accordance with Ind AS 102 - 'Share-based Payment'.

7) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad
Date : January 24, 2025



For SUVEN LIFE SCIENCES LTD

Venkata Jasti
VENKAT JASTI
Chairman & MD
DIN: 00278028

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
SUVEN LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at 6th Floor, SDE Serene Chambers, Road No 5, Banjara Hills, Hyderabad-500034, Telangana, for the quarter and nine months ended December 31, 2024 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation') as amended.

2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KARVY & CO.,
Chartered Accountants
(Firm Registration No .001757S)


DEDEE PYA NALLURI
Partner
M.No. 225106
UDIN: 25225106BM08YI4373



Place: Hyderabad
Date: January 24, 2025

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED
CONSOLIDATED FINANCIAL RESULTS**

To
The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SUVEN LIFE SCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation')
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Life Sciences Limited	Parent
Suven Neuro Sciences Inc	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies

24/01/2025




Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of the subsidiary included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. Nil, and Rs. Nil for the quarter ended and nine months period ended December 31, 2024 and total net loss after tax of Rs. (2,584.48) lakhs and Rs.(8,479.05) Lakhs for the quarter ended and nine months period ended December 31, 2024, and total comprehensive income of Rs. (2,584.48) Lakhs and Rs. (8,479.05) Lakhs for the quarter ended and nine months period ended December 31, 2024 as considered in the Statement. This interim financial information has been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on the reports of the other auditor.

Our conclusion on the statement is not modified in respect of the above matters.

For KARVY & CO.,
Chartered Accountants
(Firm Registration No .001757S)


DEDEEPPYA NALLURI
Partner
M.No. 225106
UDIN: 25225106BM08YJ9361



Place: Hyderabad
Date: January 24, 2025

24/01/2025

Statement of Deviation / Variation in utilisation of funds raised						
Name of listed entity	Suven Life Sciences Limited					
Mode of Fund Raising	Rights Issue					
Date of Raising Funds (Allotment)	16/11/2022					
Total Amount Raised (in Rs. crores)	Rs. 399.80 Crores.					
Report filed for Quarter ended	31 December, 2024					
Monitoring Agency	Applicable					
Monitoring Agency Name, if applicable	CRISIL Ratings Limited					
Is there a Deviation / Variation in use of funds raised	No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable					
If Yes, Date of shareholder Approval	Not Applicable					
Explanation for the Deviation / Variation	Not Applicable					
Comments of the Audit Committee after review	Nil					
Comments of the auditors, if any	Not Applicable					
Objects for which funds have been raised and where there has been a deviation, in the following table	As mentioned below					
Original Object	Modified Object, if any	Original Allocation (A)	Modified allocation, if any	Funds Utilized (B)	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
Meeting costs related to pharmaceutical research and development and clinical trial for molecules in the research pipelines	Not Applicable	Rs. 250.01 Crore	Not Applicable	Rs. 250.01 Crore	Not Applicable	The allocated amount fully utilized towards the said object during the quarter ended 31/12/2024.

Repayment of Inter-corporate deposit availed by Company	Not Applicable	Rs. 50.00 Crore	Not Applicable	50.00 Crore	Not Applicable	The allocated amount was fully utilized towards the said object during the quarter ended 31/12/2022.
General corporate purpose #	Not Applicable	Rs. 96.99 Crore	Not Applicable	Rs. 74.89 Crore	Not Applicable	The difference amount (A-B) of Rs. 22.10 Crore is yet to be utilized as on 31/12/2024.

Note: The Letter of Offer dated October 18, 2022, specifies that:

"In the event that there is a shortfall of funds required for research and development activities and conducting such clinical trials projects then, such shortfall shall be met out of the amounts allocated for General Corporate Purpose and/or through internal accruals." Pursuant to aforementioned disclosure, the Company has utilized the net proceeds in following manner:

Particulars	Rs. in Lakhs
Balance available for utilization towards Object 1 as at the beginning of the quarter	437.95
Proceeds utilized during the quarter for Object 1	3638.61
Shortfall met out of General Corporate Purpose*	3200.66

*The above mentioned adjustment is in line with the terms & conditions set forth in the Letter of Offer.

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

For Suvan Life Sciences Limited

M. Mohan Kumar

M. Mohan Kumar
Chief Financial Officer



- DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES: Not Applicable
- DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) — Not Applicable
- STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) — Not Applicable

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com